▎ 摘　　要

NOVELTY - Composition comprises a solubilizing agent and a conjugate compound or its salt, solvate or prodrug. USE - Composition for treating cells expressing Sortilin, and cancer or aggressive cancer in cancerous tissues or cells expressing Sortilin (all claimed), where cancer is ovarian, breast, colon and prostate cancer. The ability of composition was tested in mice implanted with MDA-MB-231 s.c. xenografts received a high dose of docetaxel (15mg/kg), TH1902 (at equivalent docetaxel dose) or vehicle, and second group of mice implanted with MDA-MB-231 s.c. xenografts received a low dose of docetaxel (3.75 mg/kg), TH1902 (at equivalent docetaxel dose) or vehicle. The results showed that TH1902 demonstrated improved tolerability (lower toxicity) and improved efficacy (stronger inhibition of Triple-negative breast cancer tumor growth) compared to docetaxel alone (at equivalent dose). ADVANTAGE - The composition prevents tumor growth or progression for a period of 10-15 days post-treatment, is effective for reducing tumor size for a period of at least 10 days, preferably 10-15 days post-treatment. DETAILED DESCRIPTION - Composition comprises a solubilizing agent and a conjugate compound or its salt, solvate or prodrug, where the conjugate compound of formula (A-(B1)n1). n1=1, 2, 3or4; A=peptide compound, which is optionally protected by a protecting group; B1=therapeutic agent, where B is connected to A optionally at a free amine of the peptide compound, at an N-terminal position of peptide compound, at a free -SH of the peptide compound, or at a free carboxyl of the peptide compound, where the peptide compound having 60% sequence identity to a compound chosen X1X2X3X4X5GVX6Ala-Lys-Ala-Gly-Val-X7-Asn-X8-Phe-Lys-Ser-Glu-Ser-Tyr (SEQ ID NO: 1), (X9)n-Gly-Val-X10-Ala-Lys-Ala-Gly-Val-X11-Asn-X12-Phe-Lys-Ser-Glu-Ser-Tyr (SEQ ID NO: 2), Tyr-Lys-X13-Leu-Arg-Arg-X14-Ala-Pro-Arg-Trp-Asp-X15-Pro-Leu-Arg-Asp-Pro-Ala-Leu-Arg-X16X17Leu (SEQ ID NO: 3), Tyr-Lys-X18-Leu-Arg-Arg(X19)n-Pro-Leu-Arg-Asp-Pro-Ala-Leu-Arg-X20X21-Leu (SEQ ID NO: 4), Ile-Lys-Leu-Ser-Gly-Gly-Val-Gln-Ala-Lys-Ala-Gly-Val-Ile-Asn-Met-Asp-Lys-Ser-Glu-Ser-Met (SEQ ID NO: 5), Ile-Lys-Leu-Ser-Gly-Gly-Val-Gln-Ala-Lys-Ala-Gly-Val-Ile-Asn-Met-Phe-Lys-Ser-Glu-Ser-Tyr (SEQ ID NO: 6), Ile-Lys-Leu-Ser-Gly-Gly-Val-Gln-Ala-Lys-Ala-Gly-Val-Ile-Asn-Met-Phe-Lys-Ser-Glu-Ser-Tyr-Lys-Lys (SEQ ID NO: 7), Gly-Val-Gln-Ala-Lys-Ala-Gly-Val-Ile-Asn-Met-Phe-Lys-Ser-Glu-Ser-Tyr (SEQ ID NO: 8), Gly-Val-Arg-Ala-Lys-Ala-Gly-Val-Arg-Asn-Met-Phe-Lys-Ser-Glu-Ser-Tyr (SEQ ID NO: 9), Gly-Val-Arg-Ala-Lys-Ala-Gly-Val-Arg-Asn(Nle)Phe-Lys-Ser-Glu-Ser-Tyr (SEQ ID NO: 10), Tyr-Lys-Ser-Leu-Arg-Arg-Lys-Ala-Pro-Arg-Trp-Asp-Ala-Pro-Leu-Arg-Asp-pro-Ala-Leu-Arg-Gln-Leu-Leu (SEQ ID NO: 11), Tyr-Lys-Ser-Leu-Arg-Arg-Lys-Ala-Pro-Arg-Trp-Asp-Ala-Tyr-Leu-Arg-Asp-Pro-Ala-Leu-Arg-Gln-leu-Leu (SEQ ID NO: 12), Tyr-Lys-Ser-Leu-Arg-Arg-Lys-Ala-Pro-Arg-Trp-Asp-Ala-Tyr-Leu-Arg-Asp-Pro-Ala-Leu-Arg-Pro-Leu-Leu (SEQ ID NO: 13); X1-X16, X19=amino acid, where X16-X21 are Q, P, Y, I or L; and n=0-5, when X9 is present more than once, each of the X9 is chosen from any amino acid, when X19 is present more than once, each of the X9 is chosen from any amino acid, where protecting group and/or labeling agent is optionally connected to the peptide compound at N- and/or C-terminal end, and optionally the peptide compound is cyclic. INDEPENDENT CLAIMS are also included for the following: (1) a method for increasing half life and/or stability of a peptide compound or its salt, solvate or prodrug, where the peptide compound having at least 60% sequence identity to the compounds or a conjugate compound or its salt, solvate or prodrug, which involves conjugating the peptide compound with molecule; (2) a method for minimizing, reducing or decreasing regrowth of tumors, which involves administering the composition to a subject; (3) a method for treating cancer or aggressive cancer, which involves administering the composition to a subject; (4) use of composition for targeting Sortilin receptor; (5) a composition, which comprises a solubilizing agent and a liposome, graphene, nanotube or nanoparticle comprising compound; and (6) a method for preparing a composition, which involves preparing a diluent solution comprising the solubilizing agent, adding the conjugate compound to the diluent solution in an amount sufficient to obtain a desired concentration, heating the solution to solubilize the conjugate compound, cooling the solution, adjusting pH of the solution to a pH of 4-4.6, optionally adding diluent to a final volume of the composition.